Influence of chemotherapy courses on the rate of bloodstream infections during neutropenia in adult acute myeloid leukaemia

Scandinavian Journal of Infectious Diseases

Volumn 40, Issue 8, 2008, Pages 642-647

  Kinnunen, Urpo ^a   Koistinen, Pirjo ^b   Ohtonen, Pasi ^b   Koskela, Markku ^b   Syrjälä, Hannu ^b  

^a LAPLAND CENTRAL HOSPITAL   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CYTARABINE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BACTERIAL GROWTH; BLOOD CULTURE; BLOODSTREAM INFECTION; CANCER CHEMOTHERAPY; CONFIDENCE INTERVAL; DISEASE DURATION; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; FUNGUS GROWTH; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MICROORGANISM; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; RETROSPECTIVE STUDY; RISK ASSESSMENT; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BACTEREMIA; FEMALE; FLOW CYTOMETRY; FUNGEMIA; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEUTROPENIA; STATISTICS, NONPARAMETRIC; YEASTS; YOUNG ADULT;

EID: 48249117539     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540801947338     Document Type: Article

References (33)

1. Safdar, N., Crnich, CJ and Maki, DG. (2006) Infectious complications of cancer therapy. pp. 1363-1400. Springer, New York
2. EOTRC International Antimicrobial Therapy Project Group (1978) Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. 137, pp. 14-29.
3. EORTC International Antimicrobial Therapy Cooperative Group (1987) Geftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteraemia in cancer patients with granulocytopenia. 317, pp. 1692-1698.
4. EORTC International Antimicrobial Therapy Cooperative Group (1993) Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. 119, pp. 584-593.
5. Bochud, P-Y, Eggiman, P., Calandra, T., van Melle, G., Saghafi, L. and Francioli, P. (1994) Bacteraemia due to viridans Streptococcus in neutropenic patients with cancer: Clinical spectrum and risk factors. 18, pp. 25-31.
6. Cordonnier, C., Buzyn, A., Leverger, G., Herbrecht, R., Hunault, M. Leclercg, R. et al. (2003) Epidemiology and risk factors for Gram-positive coccal infections in neutropenia: Towards a more targeted antibiotic strategy. 36, pp. 149-158.
7. Kinnunen, U., Syrjala, H., Koskela, M., Kujala, P. and Koistinen, P. (1996) Continuous-monitoring blood culture screening system improves the detection of bacteraemia in neutropenic patients. 28, pp. 287-292.
8. Madani, TA. (2000) Clinical infections and bloodstream isolates associated with fever in patients undergoing chemotherapy for acute myeloid leukaemia. 28, pp. 367-373.
9. Elting, LS, Rubenstein, EB, Rolston, KVI and Bodey, GP. (1997) Outcomes of bacteraemia in patients with cancer and neutropenia: Observations from 2 decades of epidemiological and clinical trials. 25, pp. 247-259.
10. Collin, BA, Leather, HL, Wingard, JR and Ramphal, R. (2001) Evolution, incidence and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. 33, pp. 947-953.
11. Engels, EA, Lau, J. and Barza, M. (1998) Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis. 16, pp. 1179-1187.
12. Wolff, SN, Herzig, RH, Fay, JW, Phillips, GL, Lazarus, HM Flexner, JM et al. (1989) High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukaemia in first remission. Long-term follow-up and results. 7, pp. 1260-1267.
13. Vogler, WR, Velez-Garcia, E., Weiner, RS, Flaum, MA, Bartolucci, AA Omura, GA et al. (1992) A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group Study. 10, pp. 1103-1111.
14. Peiris, V. and Oppenheimer, BA. (1993) Antimicrobial activity of cytotoxic drugs may influence isolation of bacteria and fungi from blood cultures. 46, pp. 1124-1125.
15. Kinnunen, U., Koistinen, P., Syrjala, H. and Koskela, M. (2001) Effects of anti-neoplastic agents on the recovery of bacteria and yeasts in an automated blood culture system. 32, pp. 63-67.
16. Nyhlen, A., Ljungberg, B., Nilsson-Ehle, I. and Odenholt, I. (2002) Bactericidal effect of combinations of antibiotic and antineoplastic agents against Staphylococcus aureus and Escherichia coli. 48, pp. 71-77.
17. Bennett, JM, Catovsky, D., Daniel, MT, Flandrin, G., Galton, DA Gralnick, HR et al. (1985) Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French-American-British Cooperative Group. 103, pp. 620-625.
18. Ruutu, T., Almqvist, A., Hallman, H., Honkanen, T., Jarvenpaa, E. Jarventie, G. et al. (1994) Oral induction and consolidation of acute myeloid leukaemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: A randomized comparison with 5-d TAD. Finnish Leukaemia Group. 8, pp. 11-15.
19. Ruutu, T., Hanninen, A., Jarventie, G., Koistinen, P., Koivunen, E. Katka, K. et al. (1997) Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukaemia following MDS with idarubicin and cytarabine. 21, pp. 133-138.
20. Ruutu, T., Koivunen, E., Nousiainen, T., Pelliniemi, TT, Almqvist, A. Anttila, P. et al. (2004) Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: A prospective randomized comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle. 72, p. 38.
21. Koistinen, P., Raty, R., Itala, M., Jantunen, E., Koivunen, E. Nousiainen, T. et al. (2007) Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): The nationwide AML-92 study by the Finnish Leukaemia Group. 78, pp. 477-485.
22. Santolaya, ME, Villarroel, M., Avendano, LF and Cofre, J. (1997) Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: A prospective study. 25, pp. 92-97.
23. Garner, JS, Jarvis, WR, Emori, TG, Horan, TC and Hughes, JM. (1996) CDC definitions for nosocomial infections. p. A1. Mosby, St. Louis
24. National Committee for Clinical Laboratory Standards (2003) Villanova PA, USA
25. E-test technical manual
26. Pepys, MB and Hirschfield, GM. (2003) C-reactive protein: A critical update. 111, pp. 1805-1812.
27. Akova, M., Paesmans, M., Calandra, T., Viscoli, C. and for the International Antimicrobial Therapy Group of the European Organization for Research and Treatment of Cancer (2005) A European organization for research and treatment of cancer: International antimicrobial therapy group study of secondary infections in febrile, neutropenic patients with cancer. 40, pp. 239-245.
28. Viscoli, C., Varnier, O. and Machetti, M. (2005) Infections in patients with febrile neutropenia: Epidemiology, microbiology, and risk stratification. 40, p. S240.
29. Costa, SF, Miceli, MH and Anaissie, EJ. (2004) Mucosa or skin as source of coagulase-negative staphylococcalbacteraemia?. 4, pp. 278-286.
30. Joel, SP and Rohatiner, A. (2002) Pharmacology of anti-leukaemic drugs 2002. pp. 394-440. Saunders, Philadelphia
31. Bassan, R. (2002) Management of infections in patients with leukemia. pp. 297-361. Saunders, Philadelphia
32. Hooper, DC and Wolfson, JS. (1993) Mechanisms of quinolone action and bacterial killing. pp. 53-75. American Society for Microbiology, Washington, DC
33. Queen, SA, Jagt, DL and Reyes, P. (1990) In vitro susceptibilities of Plasmodium falciparum to compounds, which inhibit nucleotide metabolism. 34, pp. 1393-1398.